A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors.

Trial Profile

A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Ganitumab (Primary)
  • Indications Carcinoid tumour; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 13 Jul 2016 Planned primary completion date changed from 1 Nov 2014 to 1 Aug 2016.
    • 08 Apr 2013 Planned End Date changed from 1 Nov 2011 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 01 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top